2004S-0170 - Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Section 1013: Suggest Priority Topics for Research | |||||||||||||||||||||||
FDA Comment Number : | EC47 | ||||||||||||||||||||||
Submitter : | Mr. Frederic Huser | Date & Time: | 07/07/2004 04:07:20 | ||||||||||||||||||||
Organization : | Opt-e-scrip, Inc. | ||||||||||||||||||||||
Drug Industry | |||||||||||||||||||||||
Category : | |||||||||||||||||||||||
Issue Areas/Comments | |||||||||||||||||||||||
GENERAL | |||||||||||||||||||||||
GENERAL | |||||||||||||||||||||||
Dear Sir or Madam:
Please find attached a recommendation from Opt-e-scrip, Inc. for research priorities for the Medicare Prescription Drug Benefit. Attachments include the recommendation and supporting rationale, a JAMA article in support of the recommendation, a picture of the technology described in the document, and an example of an anonymous patient report recently used by a physician for making a treatment decision. We would like to thank HHS for the opportunity to submit this reccommendation. Sincerely, Frederic Huser Chairman & CEO Opt-e-scrip, Inc. 973-699-3843 (C) | |||||||||||||||||||||||